Stanley is CEO of TaiLai Biosciences, a Chinese biotechnology company providing a new generation of biopsy products and services based on its proprietary biomultiomics technology. With over 40 years of business and healthcare experience, Stanley has served in a variety of senior roles in China and internationally with organizations including MSD, Baxter, Schering-Plough, China Biologic Products and Amsino Medical Group. He currently serves as Non-Executive Chairman of the Board of Gland Pharma and as an independent director of Solasia Pharma K.K.


University of London (BPharm)